share_log

Guggenheim Initiates Coverage On Cidara Therapeutics With Buy Rating, Announces Price Target of $33

Benzinga ·  Nov 8, 2024 22:31  · Ratings

Guggenheim analyst Seamus Fernandez initiates coverage on Cidara Therapeutics (NASDAQ:CDTX) with a Buy rating and announces Price Target of $33.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment